Across TCGA pan-cancer cohorts, RNA5SP191 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of RNA5SP191’s most consistent transcriptional readouts.
The strongest signal is observed in lung adenocarcinoma (LUAD), where RNA5SP191 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RNA5SP191 is over-expressed in tumor.
LUAD are the cancer types where RNA5SP191 tumor–normal differential expression is most reproducible.